Anti-PD-L1-Tec antibody [IHC451] (STJA0042243)
SPECIFICATIONS
ClonalityMonoclonal
HostRabbit
ConjugationUnconjugated
General Information
| Short Description | Rabbit monoclonal anti-PD-L1-Tec for use in IHC-p in Human samples. Datasheet included with dilution recommendations, and related reagents. |
| Applications | IHC-p |
| Host | Rabbit |
| Reactivity | Human |
| Note | STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Product Properties
| Clonality | Monoclonal |
| Clone ID | IHC451 |
| Conjugation | Unconjugated |
| Formulation | Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide |
| Storage Instruction | Store at 2-8°C for up to 1 year. Do not freeze. |
Target Information
| Specificity | Tested and validated on tonsil, lung adenocarcinoma tissue. |
Additional Info
| Background | Programmed Death-Ligand 1 (PD-L1) , CD274, or B7 Homolog 1 (B7-H1) , is a transmembrane protein involved in suppressing the immune system and rendering tumour cells resistant to lysis through binding of the Programmed Death-1 (PD-1) receptor. Overexpression of PD-L1 may allow cancer cells to evade the actions of the host immune system. In renal cell carcinoma, upregulation of PD-L1 has been linked to increased tumour aggressiveness and risk of death. When considered in adjunct with CD8+ tumour-infiltrating lymphocyte density, expression levels of PD-L1 may be a useful predictor of multiple cancer types, including stage III non-small-cell lung cancer, hormone receptor negative breast cancer, and sentinel lymph node melanoma. |
Information sourced from Uniprot.org